GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

The Name of the Year for 2024, according to the American Name Society, is “Ozempic," as in “Ozempic face,” “oat-zempic” and ...

Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...

but has also benefitted from supply constraints from Novo Nordisk's GLP-1 agonist Ozempic (semaglutide), a key competitor. Mason acknowledged that, noting that take-up is a "dynamic situation ...

Stock futures ticked lower on Thursday night after the Dow Jones Industrial Average and the S&P 500 ended a three-day losing streak. Futures tied to the 30-stock Dow fell 41 points, or 0.1%. S&P 500 ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...